According to Monday’s news release, the candidate, OPK-88006, is set to be the first oral GLP-1/glucagon agonist to start human studies. Under the terms of the agreement, OPKO and Entera will split ...

Opko Health and Entera Bio have formalized their partnership as the biotechs prepare to take the first orally administered dual agonist glucagonlike-peptide 1 (GLP-1)/glucagon peptide into the clinic.

Gvoke VialDx has the potential to modernize the handling and administration of glucagon for diagnostic procedures," said Kevin McCulloch, President and COO of Xeris. "American Regent is the ...